Regeneron price target lowered to $1,045 from $1,059 at RBC Capital
RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...
Regeneron price target lowered to $759 from $940 at Baird
Baird lowered the firm’s price target on Regeneron (REGN) to $759 from $940 and keeps a Neutral rating on the shares. The firms lower target ...
Regeneron's SWOT analysis: stock faces eylea challenges amid pipeline promise
Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...
Insider Monkey3d
Why Are Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now?
Baron Health Care Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2024 investor letter: “We purchased Regeneron Pharmaceuticals, Inc. (NASDAQ ...
Morningstar5d
Regeneron Pharmaceuticals Inc REGN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
pharmaphorum3d
Regeneron, Illumina join $320m Truveta investment
Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...
pharmaphorum2d
After FDA no, Regeneron gets yes from EU on odronextamab
When the FDA turned down odronextamab in a complete response letter in March, Regeneron said that it was because it had not yet started trials that would be used to confirm accelerated approvals ...